NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Liver and intrahepatic bile duct

Liver and intrahepatic bile duct

Liver and intrahepatic bile duct · 42,340 new · 30,980 deaths (ACS 2026) · mortality 6.6 per 100k · 5-yr RS 21.9% (SEER)

Mortality 6.6 per 100k (SEER / ACS common-sites). Never an artboard percent.

116,514 people living with this cancer in 2023 (SEER Stat Facts). Lifetime is not restated here — it collides with a locked artboard figure. No encoded screening interval.

116,514 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 68 · at death 70 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 13.9 / women 5.7 per 100k · mortality men 9.3 / women 4.3 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases falling 0.7% each year (2014–2023). Death rates stable (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic American Indian/Alaska Native men 23.9 per 100k. Highest death rate: Non-Hispanic American Indian/Alaska Native men 15.1 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	21.2	9.8	11.9	6.2
Non-Hispanic American Indian/Alaska Native	23.9	12.6	15.1	8.7
Non-Hispanic Asian/Pacific Islander	16.9	6.6	11.0	5.1
Non-Hispanic Black	15.5	5.5	11.6	4.7
Non-Hispanic White	11.2	4.6	8.5	3.9

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2025 · People at average risk of liver cancer · ACS (2025): there are no widely recommended screening tests for liver cancer in people who are at average risk. Higher-risk AFP and ultrasound testing is named; that calendar is not encoded. Complementary to the cited 2020 HCV/HBV viral-hepatitis statements. Not an AFP / ultrasound HCC engine.

Cited ACS statement only. Not a screening engine. ACS-liver-detect

USPSTF adjacent pointer

USPSTF 2020 B · Asymptomatic adults 18–79 without known liver disease · USPSTF 2020 Grade B: screen adults aged 18–79 for hepatitis C virus (anti-HCV, then confirmatory PCR). One-time for most adults. This is viral hepatitis screening, not liver-cancer screening. No AFP / ultrasound surveillance engine is encoded.

Cited viral-hepatitis statement only. Not a liver-cancer screening interval. USPSTF-hcv-2020

USPSTF adjacent pointer

USPSTF 2020 B · Asymptomatic nonpregnant adolescents and adults at increased risk · USPSTF 2020 Grade B: screen adolescents and adults at increased risk for hepatitis B virus (HBsAg, then confirmatory test). This is viral hepatitis screening, not liver-cancer screening. Risk groups are not encoded as an engine. No AFP / ultrasound surveillance engine is encoded.

Cited viral-hepatitis statement only. Not a liver-cancer screening interval. USPSTF-hbv-2020

Surveillance pointer

ACS-liver-follow 2025 · cited only · ACS living-as-a-survivor page names AFP, liver-function tests, and imaging after liver-cancer treatment. That calendar is not encoded. Not an AFP / ultrasound HCC engine.

Named public source only. Not a personal follow-up calendar. ACS-liver-follow

Surveillance pointer

ACS-liver-follow 2025 · cited only · ACS living-as-a-survivor page names later cancers after liver-cancer treatment, including oral cavity, ovary, kidney, and thyroid, and names colon, ovary, bladder, and AML after diagnosis before age 50. Official risk size is not known on that page and is not invented. Named later-cancer sites are not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not an AFP / ultrasound HCC engine. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-liver-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after abdomen treatment, plus fertility effects after chemo or radiation to the pelvis, belly, or spine. Those names are not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Not an AFP / ultrasound HCC engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the GI printout. Official lifetime figures are not restated. Not an AFP / ultrasound HCC engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-liver-follow 2025 · empty on purpose · ACS living-as-a-survivor page names treatment side effects that may last or appear later. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-liver-follow

Toxicity pointer

ACS-liver-follow 2025 · empty on purpose · ACS living-as-a-survivor page names later cancers after liver-cancer treatment. Those second-cancer risks are not encoded. Official lifetime figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-liver-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions and fertility effects after abdomen treatment. Those late effects are not encoded. Official lifetime figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after abdomen treatment. Those named tests are not encoded. Official lifetime figures are not restated. Complementary to the GI printout. Not an AFP / ultrasound HCC engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — GI

Acute: ACS names nausea, heartburn, cramps, diarrhea or constipation, bowel urgency, and rectal or anal skin irritation. Late: radiation proctitis, bowel incontinence, ostomy or chronic bowel change, neuropathy, adhesions, urinary trouble after pelvis RT, fertility effects, sexuality changes, lasting fatigue, cavities after chemo, and cognitive change after chemo. Monitor: on-treatment diarrhea; proctitis after 3 to 6 months; lasting fatigue or sleep problems; sexuality or body-image change; fertility after pelvis, belly, or spine treatment; cavity risk after chemo; memory, thinking, or focus change after chemo; a treatment summary and second-cancer watching. Those names are not encoded. Official esophagus share-of-new-cases figures are not restated. Not a Lynch or endoscopy engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Bowel obstruction from adhesions
Urinary retention or incontinence after pelvis RT
Fertility after pelvis, belly, or spine RT
Sexuality after cancer treatment
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment
Cavities and tooth loss after chemo
Cognitive impairment after brain RT or chemo

Named conditions to monitor

Diarrhea that starts during abdomen RT
Radiation proctitis after 3 to 6 months
Second-cancer testing
Bowel blockage or bladder-emptying trouble
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Sexuality or body-image change after treatment
Fertility after pelvis, belly, or spine treatment
Cavity risk after chemo
New or worsening memory, thinking, or focus
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS abdomen / pelvis / CRC names only. Complementary ACS long-term page is named, not encoded. Official esophagus share-of-new-cases figures are not restated. No invented trial percent.

Open GI printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-liver · stub · none · v2-stub-liver

SEER 5-year relative survival by stage (cited stub)

Localized 37.4% · Regional 13.4% · Distant 3.6% · All 21.9%

Lifetime is not restated here — it collides with a locked artboard figure.

Percent of cases by stage (SEER Stat Facts)

Localized 45% · Regional 23% · Distant 21% · Unknown 10%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Lifetime is not restated here.

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF liver-cancer screen — HCV/HBV are adjacent only
Cited ACS 2025 average-risk no-screen note plus 2020 HCV/HBV Grade B. Not an AFP / ultrasound HCC engine.
not encoded
surveillance
ACS follow-up cited — AFP / imaging months not encoded
Cited ACS living-as-a-survivor page plus HCV/HBV adjacent notes. Not an AFP / ultrasound HCC engine.
not encoded
toxicity
ACS late effects cited — liver months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF liver-cancer screen — HCV/HBV are adjacent only
Cited ACS 2025 average-risk no-screen note plus 2020 HCV/HBV Grade B. Not an AFP / ultrasound HCC engine.
not encoded
surveillance
ACS follow-up cited — AFP / imaging months not encoded
Cited ACS living-as-a-survivor page plus HCV/HBV adjacent notes. Not an AFP / ultrasound HCC engine.
not encoded
toxicity
ACS late effects cited — liver months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF liver-cancer screen — HCV/HBV are adjacent only
Cited ACS 2025 average-risk no-screen note plus 2020 HCV/HBV Grade B. Not an AFP / ultrasound HCC engine.
not encoded
surveillance
ACS follow-up cited — AFP / imaging months not encoded
Cited ACS living-as-a-survivor page plus HCV/HBV adjacent notes. Not an AFP / ultrasound HCC engine.
not encoded
toxicity
ACS late effects cited — liver months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF liver-cancer screen — HCV/HBV are adjacent only
Cited ACS 2025 average-risk no-screen note plus 2020 HCV/HBV Grade B. Not an AFP / ultrasound HCC engine.
not encoded
surveillance
ACS follow-up cited — AFP / imaging months not encoded
Cited ACS living-as-a-survivor page plus HCV/HBV adjacent notes. Not an AFP / ultrasound HCC engine.
not encoded
toxicity
ACS late effects cited — liver months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →